The raised guidance and strong Q1 beat across both franchises (MACI +22%, Burn Care +91%) signal accelerating commercial momentum. The FDA approval for the new manufacturing facility removes a key capacity overhang. Watch for continued MACI implant growth and NexoBrid BARDA contract execution in coming quarters.
Price Chart
Executive Summary
Vericel reported Q1 2026 total revenue of $68.4M (+30% YoY), beating the $63.6M consensus, and a GAAP net loss of $0.12/share, which is narrower than the $-0.14 Street consensus. The company raised its full-year 2026 revenue guidance by $10M to $326-336M, driven by 22% MACI growth and 91% Burn Care growth, while maintaining profitability margin targets.
Key Financial Metrics
Key Facts
- Total Q1 2026 revenue of $68.4M, up 30% YoY from $52.6M, beating $63.6M consensus
- GAAP net loss of $6.3M ($0.12/diluted share) vs $11.2M loss ($0.23) in Q1 2025, narrower than $-0.14 Street consensus
- Full-year 2026 revenue guidance raised by $10M to $326-336M (from $316-326M)
- MACI revenue grew 22% to $56.4M; Burn Care revenue surged 91% to $12.0M
- Adjusted EBITDA grew 195% to $9.6M (14% of revenue) from $3.2M (6%)
- Operating cash flow of $16.4M and free cash flow of $15.1M, vs negative FCF of $7.6M in Q1 2025
- Received FDA approval for MACI commercial manufacturing at new Burlington facility
- Announced BARDA award valued at up to $197M for NexoBrid procurement and development
Financial Impact
Revenue beat consensus by ~7.5% ($68.4M vs $63.6M); EPS loss of $0.12 was ~14% better than $-0.14 consensus; full-year guidance raised by $10M (+3.1% at midpoint)
Risk Factors
- GAAP net loss persists despite revenue growth; profitability dependent on operating leverage
- Execution risk on new Burlington facility ramp and MACI manufacturing scale-up
- Burn Care revenue can be lumpy due to episodic burn events and Epicel ordering patterns
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-031713 |
| Document: vcel-20260507.htm | 0001628280-26-031713 |
| Document: 0001628280-26-031713-index-headers.html | 0001628280-26-031713 |
| Document: 0001628280-26-031713-index.html | 0001628280-26-031713 |
| Document: 0001628280-26-031713.txt | 0001628280-26-031713 |
| 8-K Data (Synthetic) | 0001628280-26-031713 |
Track record
30 reports on VCEL
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +31.08% at T+60 after the May 7, 2026 report. 2 of 4 went positive at some point.
Filters
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $56.96 Now $57.48 +0.91% settles Feb 11
- Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $56.96 Now $57.48 +0.91% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 1/10 Entry $57.42 Now $57.48 +0.10% settles Feb 10
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $59.03 Now $57.48 −2.63% settles Feb 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $59.03 Now $57.48 −2.63% settles Feb 8
- Nov 9, 20267d ago 144 Neutral 3/10 Entry $59.03 Now $57.48 −2.63% settles Feb 8
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $59.03 Now $57.48 −2.63% settles Feb 8
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $58.39 Now $57.48 −1.56% settles Feb 5
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $58.39 Now $57.48 −1.56% settles Feb 5
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $54.62 Now $57.48 +5.24% settles Feb 4
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers